Correlation between serum cystatin C and lipid level in patients with chronic heart failure

Fengyang Ni1, Yu Xiang2

  • 1Department of Cardiovascular Medicine, 521 Hospital of Norinco Group, Xi'an 710065. single520zx202201@126.com.

Insights

In chronic heart failure (CHF) patients, lower high-density lipoprotein (HDL) levels are linked to abnormal serum cystatin C (Cys C). This finding suggests HDL may be the sole blood lipid indicator associated with Cys C abnormalities in CHF.

Area of Science:

  • Cardiology
  • Clinical Biochemistry
  • Nephrology

Background:

  • Serum cystatin C (Cys C) and blood lipids are implicated in chronic heart failure (CHF).
  • Limited research exists on the relationship between serum Cys C and blood lipids in CHF patients.
  • Understanding this correlation can aid CHF diagnosis and treatment.

Purpose of the Study:

  • To investigate the association between serum Cys C levels and blood lipid profiles in patients with CHF.
  • To provide clinical insights for managing CHF.

Main Methods:

  • 336 hospitalized CHF patients were categorized into Cys C normal (n=180) and abnormal (n=156) groups.
  • General data, laboratory markers, and echocardiographic results were compared.
  • Pearson correlation and multivariate logistic regression analyses were employed.

Main Results:

  • The Cys C abnormal group exhibited lower left ventricular ejection fraction (LVEF), older age, and higher rates of diabetes and smoking.
  • Abnormal Cys C was associated with elevated serum creatinine (SCr), blood urea nitrogen (BUN), and total bilirubin (TBIL).
  • Serum Cys C showed negative correlations with high-density lipoprotein (HDL), apolipoprotein A (Apo A), and albumin (ALB).

Conclusions:

  • Decreased HDL levels were identified as a risk factor for abnormal serum Cys C in CHF patients.
  • Apo A was not found to be a risk factor for abnormal serum Cys C.
  • HDL may be the primary blood lipid marker associated with serum Cys C abnormalities in CHF.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
133
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
214
Serum Studies: Renal Function Tests01:24

Serum Studies: Renal Function Tests

Renal function tests are crucial for assessing kidney health, monitoring disease progression, and evaluating the kidneys' efficiency in waste elimination, fluid balance, and electrolyte regulation. These tests offer critical insights into kidney function, even though routine measurements may appear normal until there is a significant decline in the glomerular filtration rate or GFR. Typically, signs of kidney impairment only become evident when the GFR falls to about 50% of its normal level.
26
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
50
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT01:25

Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT

Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
51
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
20